TY - JOUR
T1 - Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
AU - Kaseb, Ahmed Omar
AU - Hassan, Manal
AU - Lacin, Sahin
AU - Abdel-Wahab, Reham
AU - Amin, Hesham M.
AU - Shalaby, Ahmed
AU - Wolff, Robert A.
AU - Yao, James
AU - Rashid, Asif
AU - Vennapusa, Bharathi
AU - Feng, Janine
AU - Ohtomo, Toshihiko
PY - 2016
Y1 - 2016
N2 - Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. In patients with HCC, histopathogical differentiation is an important indicator of prognosis; however, because determination of HCC differentiation is difficult, the recently described immunohistochemical (IHC) marker glypican3 (GPC3) might assist in HCC prognostication. The goal of our study was to investigate GPC3's IHC staining pattern and define the relationship between its expression and patients' clinicopathologic features and overall survival. We retrieved clinical parameters from 101 pathologically diagnosed HCC patients' medical records and classified these patients into 4 clinical score categories (0-3) based on increasing GPC3 staining intensity and the percentage of stained tumor cells in their resection and biopsy specimens. Histopathological samples were well, moderately, and poorly differentiated in 33, 22, and 12 patients, respectively, and the GPC3 expression rate was 63%, 86%, and 92%,respectively. The median overall survival was 49.9 months (confidence interval (CI): 35.3-64.6 months) for clinical scores 0-1 and 30.7 months (CI: 19.4-41.9 months) for clinical scores 2-3. This difference was not statistically significant (P =.06) but showed a strong trend. In conclusion, a greater GPC3 expression is associated with a worse HCC prognosis and may be a promising prognostic marker.
AB - Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. In patients with HCC, histopathogical differentiation is an important indicator of prognosis; however, because determination of HCC differentiation is difficult, the recently described immunohistochemical (IHC) marker glypican3 (GPC3) might assist in HCC prognostication. The goal of our study was to investigate GPC3's IHC staining pattern and define the relationship between its expression and patients' clinicopathologic features and overall survival. We retrieved clinical parameters from 101 pathologically diagnosed HCC patients' medical records and classified these patients into 4 clinical score categories (0-3) based on increasing GPC3 staining intensity and the percentage of stained tumor cells in their resection and biopsy specimens. Histopathological samples were well, moderately, and poorly differentiated in 33, 22, and 12 patients, respectively, and the GPC3 expression rate was 63%, 86%, and 92%,respectively. The median overall survival was 49.9 months (confidence interval (CI): 35.3-64.6 months) for clinical scores 0-1 and 30.7 months (CI: 19.4-41.9 months) for clinical scores 2-3. This difference was not statistically significant (P =.06) but showed a strong trend. In conclusion, a greater GPC3 expression is associated with a worse HCC prognosis and may be a promising prognostic marker.
KW - Glypican-3
KW - Hepatocellular carcinoma
KW - Immunohistochemistry
UR - http://www.scopus.com/inward/record.url?scp=84994355368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994355368&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.12066
DO - 10.18632/oncotarget.12066
M3 - Article
C2 - 27655712
AN - SCOPUS:84994355368
SN - 1949-2553
VL - 7
SP - 69916
EP - 69926
JO - Oncotarget
JF - Oncotarget
IS - 43
ER -